Articles by Daniel Marsh
Staffing Stocks Surge 39% in August as Temp Hiring Jumps 4.4%
U.S. staffing stocks jumped 39% in August as temp hiring grew 4.4%, with Kelly Services, TrueBlue, AMN Healthcare, and ManpowerGroup posting triple-digit gains.
Treasury Yields Jump as Warsh Signals September Rate Hike
Two-year Treasury yield jumps 9.5 bps to 4.325% as Fed Chair Warsh's inflation comments lift September rate hike odds to 55.7%. 10-year yield rises to 4.70%.
Femasys Soars 15% as UNC Health Adopts Fertility Tech Across Clinics
Femasys shares surged 15% after UNC Health agreed to deploy FemaSeed fertility products across its OB/GYN clinics, boosting investor confidence despite weak quarterly sales.
Rivian CFO Exit Sparks 6.5% Stock Drop Amid R2 Ramp-Up
Rivian shares dropped 6.5% after CFO Claire McDonough announced departure, fueling concerns about R2 production ramp-up and cost control. Interim CFO Derek Mulvey appointed.
Swvl Soars 34% on $14.5M Funding for U.S. Expansion
Swvl (SWVL) shares surged 34% after a $14.5M strategic investment to fund U.S. expansion, with new shares nearly doubling outstanding count.
Investors Pull $22.3B from U.S. Equity Funds in Largest Outflow Since March
U.S. equity funds posted $22.33B in outflows, the largest since March, as large-cap withdrawals dwarfed small-cap inflows. Bond funds saw $7.12B inflows.
Callaway Gains After Cutting Ties with Good Good, Commits $1M
Callaway shares climbed 2.5% after terminating its Good Good Golf partnership and pledging $1 million to anti-violence groups, a move analysts see as a brand-risk reset.
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.
SharonAI Tumbles 4.2% as Nvidia Pauses Cloud Financing, Clouding $4.88B Deal
SharonAI shares dropped 4.2% after Nvidia paused parts of a cloud financing initiative, raising questions about its $4.88 billion compute agreement.
Cytokinetics Drops 5% Despite Positive Phase 3 Data in nHCM
Cytokinetics shares slid 5% despite positive Phase 3 trial results for MYQORZO in non-obstructive HCM, as investors hoped for larger clinical benefits.
BioNTech Slumps 6.6% as Colorectal Cancer Vaccine Trial Halted
BioNTech shares dropped 6.6% after the company ended a Phase 2 trial of its colorectal cancer vaccine. The decision follows a data safety board recommendation and erases about $1.8 billion in market value.